Concepts (197)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chest Pain | 25 | 2020 | 207 | 6.240 |
Why?
|
| Emergency Service, Hospital | 27 | 2020 | 471 | 4.110 |
Why?
|
| Acute Coronary Syndrome | 18 | 2020 | 193 | 3.850 |
Why?
|
| Myocardial Infarction | 18 | 2020 | 480 | 2.230 |
Why?
|
| Patient Discharge | 7 | 2019 | 183 | 1.610 |
Why?
|
| Cardiology Service, Hospital | 3 | 2015 | 23 | 1.380 |
Why?
|
| Risk Assessment | 16 | 2020 | 1431 | 1.260 |
Why?
|
| Electrocardiography | 16 | 2020 | 632 | 1.250 |
Why?
|
| Coronary Angiography | 8 | 2018 | 148 | 1.240 |
Why?
|
| Exercise Test | 5 | 2019 | 225 | 1.060 |
Why?
|
| Troponin | 10 | 2020 | 106 | 1.050 |
Why?
|
| Middle Aged | 39 | 2020 | 11824 | 1.000 |
Why?
|
| Coronary Artery Disease | 3 | 2018 | 398 | 0.860 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2013 | 1323 | 0.830 |
Why?
|
| Male | 42 | 2020 | 19091 | 0.820 |
Why?
|
| Female | 42 | 2020 | 19859 | 0.800 |
Why?
|
| Aged | 29 | 2020 | 10288 | 0.780 |
Why?
|
| Length of Stay | 5 | 2015 | 315 | 0.770 |
Why?
|
| Decision Support Techniques | 4 | 2020 | 128 | 0.750 |
Why?
|
| Inpatients | 3 | 2011 | 81 | 0.720 |
Why?
|
| Predictive Value of Tests | 11 | 2020 | 874 | 0.690 |
Why?
|
| Humans | 49 | 2020 | 31836 | 0.690 |
Why?
|
| Angina Pectoris | 2 | 2013 | 22 | 0.690 |
Why?
|
| Adult | 25 | 2020 | 9327 | 0.640 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 48 | 0.620 |
Why?
|
| Hospitalization | 7 | 2020 | 463 | 0.580 |
Why?
|
| Troponin C | 1 | 2017 | 9 | 0.570 |
Why?
|
| Logistic Models | 9 | 2020 | 777 | 0.570 |
Why?
|
| Observation | 2 | 2013 | 25 | 0.560 |
Why?
|
| Anticoagulants | 4 | 2011 | 122 | 0.550 |
Why?
|
| Critical Pathways | 4 | 2018 | 48 | 0.540 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2017 | 912 | 0.540 |
Why?
|
| Emergency Medicine | 2 | 2008 | 120 | 0.510 |
Why?
|
| Odds Ratio | 6 | 2020 | 470 | 0.500 |
Why?
|
| Retrospective Studies | 11 | 2019 | 3488 | 0.490 |
Why?
|
| North Carolina | 8 | 2020 | 1514 | 0.460 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2008 | 82 | 0.440 |
Why?
|
| Vasodilator Agents | 1 | 2013 | 59 | 0.430 |
Why?
|
| Emergency Treatment | 1 | 2013 | 41 | 0.430 |
Why?
|
| Sterol O-Acyltransferase | 1 | 2012 | 11 | 0.420 |
Why?
|
| Heart Diseases | 2 | 2011 | 115 | 0.410 |
Why?
|
| Triage | 2 | 2010 | 72 | 0.410 |
Why?
|
| Coronary Vessels | 1 | 2013 | 158 | 0.400 |
Why?
|
| Myocardial Revascularization | 3 | 2018 | 40 | 0.400 |
Why?
|
| Risk Factors | 9 | 2020 | 3851 | 0.390 |
Why?
|
| Time Factors | 8 | 2020 | 2146 | 0.390 |
Why?
|
| Hospital Costs | 1 | 2011 | 37 | 0.390 |
Why?
|
| Coronary Stenosis | 1 | 2011 | 30 | 0.380 |
Why?
|
| Health Expenditures | 1 | 2011 | 66 | 0.380 |
Why?
|
| Prospective Studies | 10 | 2020 | 2277 | 0.380 |
Why?
|
| Patient Admission | 1 | 2011 | 60 | 0.380 |
Why?
|
| Fibrinolytic Agents | 2 | 2008 | 70 | 0.370 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2007 | 61 | 0.360 |
Why?
|
| Registries | 7 | 2015 | 295 | 0.360 |
Why?
|
| Diagnosis, Differential | 5 | 2020 | 518 | 0.350 |
Why?
|
| Health Services | 1 | 2010 | 38 | 0.340 |
Why?
|
| Delivery of Health Care | 1 | 2011 | 159 | 0.340 |
Why?
|
| Pulmonary Embolism | 4 | 2011 | 49 | 0.340 |
Why?
|
| Peptide Fragments | 2 | 2009 | 398 | 0.340 |
Why?
|
| Research Support as Topic | 1 | 2008 | 26 | 0.320 |
Why?
|
| Acute Disease | 8 | 2020 | 252 | 0.310 |
Why?
|
| United States | 12 | 2020 | 3925 | 0.300 |
Why?
|
| Cohort Studies | 8 | 2018 | 1824 | 0.300 |
Why?
|
| Drug Utilization Review | 1 | 2007 | 17 | 0.300 |
Why?
|
| Reproducibility of Results | 6 | 2017 | 764 | 0.290 |
Why?
|
| Severity of Illness Index | 8 | 2018 | 899 | 0.280 |
Why?
|
| Biomedical Research | 1 | 2008 | 155 | 0.280 |
Why?
|
| Prognosis | 4 | 2015 | 1498 | 0.260 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2005 | 108 | 0.250 |
Why?
|
| Myocardial Ischemia | 2 | 2008 | 106 | 0.250 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 4 | 2008 | 30 | 0.230 |
Why?
|
| Heart Failure | 5 | 2010 | 620 | 0.230 |
Why?
|
| Craniocerebral Trauma | 2 | 2015 | 56 | 0.230 |
Why?
|
| Postural Balance | 1 | 2016 | 182 | 0.230 |
Why?
|
| Coronary Disease | 1 | 2005 | 213 | 0.230 |
Why?
|
| Decision Making | 3 | 2016 | 194 | 0.230 |
Why?
|
| Pesticides | 1 | 2016 | 200 | 0.220 |
Why?
|
| Emergency Medical Services | 2 | 2018 | 178 | 0.220 |
Why?
|
| Occupational Exposure | 1 | 2016 | 233 | 0.220 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 2271 | 0.210 |
Why?
|
| Transients and Migrants | 1 | 2016 | 291 | 0.210 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 245 | 0.210 |
Why?
|
| Age Factors | 4 | 2018 | 1187 | 0.200 |
Why?
|
| Hispanic Americans | 2 | 2020 | 942 | 0.200 |
Why?
|
| Comorbidity | 3 | 2009 | 566 | 0.190 |
Why?
|
| Aged, 80 and over | 7 | 2013 | 3988 | 0.190 |
Why?
|
| Patient Readmission | 2 | 2013 | 113 | 0.180 |
Why?
|
| Multicenter Studies as Topic | 3 | 2010 | 103 | 0.170 |
Why?
|
| Mortality | 1 | 2020 | 124 | 0.170 |
Why?
|
| Sensitivity and Specificity | 4 | 2020 | 589 | 0.170 |
Why?
|
| Hemorrhage | 3 | 2015 | 100 | 0.170 |
Why?
|
| Pain Measurement | 2 | 2019 | 351 | 0.170 |
Why?
|
| Enoxaparin | 2 | 2009 | 20 | 0.160 |
Why?
|
| Clinical Trials as Topic | 3 | 2010 | 297 | 0.160 |
Why?
|
| Heparin | 2 | 2009 | 74 | 0.160 |
Why?
|
| Hospital Mortality | 3 | 2009 | 190 | 0.150 |
Why?
|
| Ethnic Groups | 1 | 2020 | 476 | 0.150 |
Why?
|
| Troponin T | 1 | 2018 | 80 | 0.140 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 94 | 0.130 |
Why?
|
| Death | 1 | 2015 | 50 | 0.130 |
Why?
|
| Incidence | 3 | 2016 | 1192 | 0.130 |
Why?
|
| Algorithms | 1 | 2018 | 495 | 0.130 |
Why?
|
| Echocardiography, Stress | 1 | 2015 | 27 | 0.130 |
Why?
|
| Spinal Cord Injuries | 1 | 2015 | 39 | 0.120 |
Why?
|
| Hypotension | 1 | 2015 | 47 | 0.120 |
Why?
|
| Clinical Protocols | 1 | 2015 | 99 | 0.120 |
Why?
|
| Confidence Intervals | 2 | 2011 | 148 | 0.110 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2010 | 18 | 0.110 |
Why?
|
| Efficiency, Organizational | 1 | 2013 | 19 | 0.110 |
Why?
|
| Shock | 1 | 2013 | 29 | 0.110 |
Why?
|
| Sex Factors | 3 | 2020 | 662 | 0.110 |
Why?
|
| Hirudins | 2 | 2009 | 19 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 1122 | 0.100 |
Why?
|
| Forecasting | 2 | 2010 | 144 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2009 | 3294 | 0.100 |
Why?
|
| Radionuclide Imaging | 1 | 2011 | 26 | 0.100 |
Why?
|
| Mass Spectrometry | 1 | 2012 | 103 | 0.100 |
Why?
|
| Academic Medical Centers | 2 | 2010 | 156 | 0.100 |
Why?
|
| Recombinant Proteins | 2 | 2009 | 247 | 0.100 |
Why?
|
| Coronary Care Units | 1 | 2011 | 4 | 0.100 |
Why?
|
| Models, Economic | 1 | 2011 | 20 | 0.100 |
Why?
|
| Tomography, X-Ray | 1 | 2011 | 5 | 0.100 |
Why?
|
| Cost Savings | 1 | 2011 | 34 | 0.100 |
Why?
|
| Drug Costs | 1 | 2011 | 47 | 0.100 |
Why?
|
| Adenosine | 1 | 2011 | 59 | 0.100 |
Why?
|
| Dobutamine | 1 | 2011 | 68 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 756 | 0.090 |
Why?
|
| Echocardiography | 1 | 2011 | 155 | 0.090 |
Why?
|
| Myocardium | 1 | 2011 | 186 | 0.090 |
Why?
|
| Heart | 1 | 2011 | 178 | 0.090 |
Why?
|
| Linear Models | 1 | 2011 | 449 | 0.090 |
Why?
|
| Medical Audit | 1 | 2010 | 16 | 0.090 |
Why?
|
| Carbon Dioxide | 1 | 2010 | 37 | 0.090 |
Why?
|
| Costs and Cost Analysis | 1 | 2010 | 100 | 0.090 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2009 | 38 | 0.090 |
Why?
|
| Safety Management | 1 | 2010 | 37 | 0.090 |
Why?
|
| Venous Thromboembolism | 1 | 2010 | 28 | 0.090 |
Why?
|
| Oxygen | 1 | 2010 | 140 | 0.080 |
Why?
|
| Program Evaluation | 1 | 2010 | 184 | 0.080 |
Why?
|
| Information Services | 1 | 2009 | 15 | 0.080 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2009 | 66 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 298 | 0.080 |
Why?
|
| Coronary Thrombosis | 1 | 2008 | 14 | 0.080 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2008 | 28 | 0.080 |
Why?
|
| Dyspnea | 1 | 2008 | 32 | 0.080 |
Why?
|
| Ticlopidine | 1 | 2008 | 17 | 0.080 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2008 | 14 | 0.080 |
Why?
|
| Tyrosine | 1 | 2008 | 23 | 0.080 |
Why?
|
| Pyridines | 1 | 2008 | 76 | 0.080 |
Why?
|
| Aspirin | 1 | 2008 | 64 | 0.070 |
Why?
|
| Heart Conduction System | 1 | 2008 | 75 | 0.070 |
Why?
|
| Continuity of Patient Care | 1 | 2008 | 69 | 0.070 |
Why?
|
| Peptides | 1 | 2008 | 119 | 0.070 |
Why?
|
| Patient Selection | 2 | 2008 | 276 | 0.070 |
Why?
|
| Quality Indicators, Health Care | 1 | 2007 | 59 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 1527 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2007 | 119 | 0.070 |
Why?
|
| Coronary Artery Bypass | 1 | 2007 | 100 | 0.070 |
Why?
|
| Recurrence | 1 | 2007 | 262 | 0.070 |
Why?
|
| Cause of Death | 1 | 2007 | 238 | 0.070 |
Why?
|
| Research Design | 1 | 2008 | 310 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 244 | 0.070 |
Why?
|
| Singapore | 1 | 2005 | 10 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2004 | 44 | 0.060 |
Why?
|
| Survival Rate | 2 | 2018 | 884 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 404 | 0.060 |
Why?
|
| Injury Severity Score | 2 | 2015 | 111 | 0.060 |
Why?
|
| Adolescent | 4 | 2015 | 3511 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2016 | 895 | 0.060 |
Why?
|
| Prevalence | 1 | 2005 | 979 | 0.050 |
Why?
|
| Infant | 2 | 2015 | 1055 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2015 | 1259 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 44 | 0.050 |
Why?
|
| Child | 2 | 2015 | 2425 | 0.040 |
Why?
|
| European Continental Ancestry Group | 1 | 2020 | 1169 | 0.030 |
Why?
|
| Glasgow Coma Scale | 1 | 2015 | 27 | 0.030 |
Why?
|
| Trauma Centers | 1 | 2015 | 82 | 0.030 |
Why?
|
| African Americans | 1 | 2020 | 1428 | 0.030 |
Why?
|
| Age Distribution | 1 | 2013 | 206 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2015 | 665 | 0.030 |
Why?
|
| Nitroglycerin | 1 | 2010 | 11 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2013 | 249 | 0.020 |
Why?
|
| Exhalation | 1 | 2010 | 3 | 0.020 |
Why?
|
| Capnography | 1 | 2010 | 9 | 0.020 |
Why?
|
| Tomography, Spiral Computed | 1 | 2010 | 18 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2010 | 45 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2009 | 23 | 0.020 |
Why?
|
| Observer Variation | 1 | 2009 | 105 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 167 | 0.020 |
Why?
|
| Disease Management | 1 | 2010 | 126 | 0.020 |
Why?
|
| Syndrome | 1 | 2009 | 73 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 131 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 564 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 686 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2005 | 487 | 0.010 |
Why?
|
| Cardiology | 1 | 2005 | 99 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 2603 | 0.010 |
Why?
|